News / Press Release
| Date | News |
|---|---|
| December 01, 2020 | Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020LA CHAUX DU FONDS, Switzerland–(BUSINESS WIRE)–Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. |
| October 12, 2020 | Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater ChinaExclusive licensing agreement for the development and commercialization of Tenalisib, a dual PI3K delta & gamma inhibitor in the Greater China region. |
| September 24, 2020 | Rhizen Pharmaceuticals S.A. Announces Publication of Clinical Data from the Phase I/Ib study of Tenalisib (RP6530) in Patients with Relapsed/Refractory T-Cell Lymphoma (TCL)Results from the Phase I/Ib study of Tenalisib (RP6530), the company’s novel next generation dual PI3K δ/γ inhibitor, in the journal Cancers. Single-agent Tenalisib was well tolerated with a good overall response rate (ORR) in both peripheral and cutaneous T-cell Lymphoma patients (PTCL and CTCL). |
| October 22, 2019 | Rhizen Pharmaceuticals S.A. announces poster presentations of RP7214, a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) in preclinical models of Acute Myeloid Leukemia (AML) at the 2019 AACR-NCI-EORTC ConferenceRP7214, a novel small molecule inhibitor of DHODH in preclinical models of Acute Myeloid Leukemia (AML) demonstrated anti-tumor activities manifested by a reduction in both tumor size and tumor weight in MV-4-11 human leukemia xenograft model when combined with cytarabine (ARA-C). |
| October 22, 2019 | Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class store-operated calcium entry (SOCE) inhibitor in preclinical models of Acute Myeloid Leukemia (AML) at the 2019 AACR-NCI-EORTC Conference in BostonRP4010 is a novel first-in-class oral small molecule inhibitor of store-operated calcium entry (SOCE) with demonstrated preclinical activity in a broad range of cancers. |
| March 26, 2019 | Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor in preclinical models of Gastrointestinal (GI) Cancers at the 2019 AACR Annual MeetingRP4010 is a novel first-in-class oral small molecule inhibitor of calcium release activated calcium (CRAC) channel pathway with demonstrated preclinical activity in a broad range of cancers. RP4010 significantly enhanced the activity of everolimus in Pancreatic Neuroendocrine Tumors (PNETs). |
| May 29, 2018 | Rhizen Pharmaceuticals S.A. Announces Presentations on Tenalisib (RP6530) at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingPhase I/II clinical development progress in Relapsed/Refractory T-cell Lymphoma (R/R TCL) and Relapsed/Refractory classical Hodgkin Lymphoma (R/R cHL). |
| April 13, 2018 | Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for Tenalisib (RP6530), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (CTCL)Tenalisib (RP6530) has been granted Fast Track Designation, demonstrating the FDA’s commitment to facilitate the development and expedite the review of highly selective and orally active dual PI3K delta/gamma inhibitor as an important therapy for patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (R/R CTCL). |
| April 10, 2018 | Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual MeetingPreclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor and RP10107, a novel and potent glutaminase inhibitor in hematological malignancies and solid tumors. |
| April 09, 2018 | Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)US FDA orphan-drug designations for the active moiety of Tenalisib (RP6530) for the treatment of peripheral and cutaneous T-cell Lymphoma (PTCL and CTCL) in the United States. |
| January 29, 2018 | Rhizen Pharmaceuticals S.A. announces clinical data presentations for Tenalisib (RP6530) in R/R T-cell lymphoma at the upcoming 10th Annual T-Cell Lymphoma Forum in La Jolla, CA, USAPpdated clinical data for Tenalisib (RP6530), highly selective and orally active dual PI3K delta/gamma inhibitor, has been selected for oral and poster presentations at the upcoming 10th Annual T-Cell Lymphoma Forum. |
| December 22, 2017 | Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the active moiety of Tenalisib (RP6530). |
| December 09, 2017 | Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for RP6530 (tenalisib), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL)RP6530 (tenalisib) has been granted Fast Track Designation, demonstrating the FDA’s commitment to facilitate the development and expedite the review of selective and orally active dual PI3K delta/gamma inhibitor as an important therapy for patients with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) |
| December 05, 2017 | Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USARP6530 (tenalisib) updated data from ongoing Phase I/IB study: Demonstrated highly promising single-agent clinical activity with acceptable safety in relapsed/refractory T-cell Lymphoma. |
| October 24, 2017 | Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at 2017 AACR-NCI-EORTC International Conference, USAPeclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor in hematological malignancies and solid tumors |
| December 09, 2015 | Rhizen Pharmaceuticals Announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3K-delta gamma InhibitorWorldwide license agreement with Novartis for the development and commercialization of Rhizen’s, inhaled dual PI3K-delta gamma inhibitor and its closely related compounds for various indications. |
| September 22, 2015 | Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell LymphomaA Phase 1 dose escalation study of RV1001 was completed with the drug showing remarkable single agent activity in T- and B-cell Non-Hodgkin’s Lymphoma (NHL) in dogs with acceptable safety. |
| December 03, 2014 | Rhizen Pharmaceuticals S.A. to present Phase 1 clinical and additional preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in hematological malignanciesRP6530 demonstrated excellent safety across four dose levels;25 mg BID, 50 mg BID, 100 mg BID and 200 mg BID. No increase in ALT/AST, colitis, pneumonia, or drug related neutropenia reported among treated patients. |
| November 18, 2014 | Rhizen Pharmaceuticals S.A. to present preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in Multiple MyelomaRP6530 synergizes with standard Multiple Myeloma (MM) therapy such as bortezomib (VELCADE ®) in MM representative cell lines. RP6530 increases survival with the effect being superior to standard doses of bortezomib. |
| September 23, 2014 | Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta InhibitorOut-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG Therapeutics exercised its option for early conversion to a licensing agreement from a 50:50 joint venture partnership. |
| September 03, 2014 | Rhizen Pharmaceuticals S.A. to present preclinical data of their first-in-class inflammation assets, RP6503 and RP3128 for treatment of various respiratory diseasesData for lead first-in-class inflammation/auto-immune assets, RP6503 and RP3128 in preclinical models of pulmonary fibrosis, COPD and asthma. |
| December 06, 2013 | Rhizen Pharmaceuticals S.A. announces initiation of a "First in Human" Phase-1 trial of RP6530, a dual PI3K delta/gamma inhibitor, in patients with hematological malignanciesInitiation of a "first in human" Phase-1 study of RP6530, a dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, for the treatment of patients with advanced hematological malignancies. |
| November 19, 2013 | Rhizen Pharmaceuticals S.A. announces preclinical presentations on RP6530, a dual PI3K delta/gamma inhibitor, for the treatment of hematological malignancies at the 55th Annual Meeting of the American Society of Hematology, 2013RP6530 is a best-in-class, highly selective, equipotent, and orally active dual PI3K delta/gamma inhibitor with impressive activity against several cell types representative of various leukemias/lymphomas. |
| September 09, 2013 | Rhizen Pharmaceuticals S.A Announces a Scientific Presentation on the PI3K-Delta Inhibitor, TGR-1202, at the XV International Workshop on Chronic Lymphocytic Leukemia at Cologne, GermanyRhizen has partnered TGR-1202 with TG Therapeutics, USA, as a global joint venture.TGR-1202 is currently in Phase I clinical development for patients with hematologic malignancies. |
| September 06, 2013 | Rhizen Pharmaceuticals S.A. announces scientific presentations on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor and CRAC channel inhibitor at the ERS Annual Conference at Barcelona, Spain, 7-11 September 2013Pre-clinical characterization of calcium release activated channel (CRAC) inhibitor, RP3128, for the treatment of respiratory disorders and pharmacological profile of dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, RP6503, in the pulmonary disease systems. |
| June 12, 2013 | Rhizen Pharmaceuticals S.A. announces a scientific presentation on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor in T-cell Lymphomas at the 18th Congress of European Hematology Association, 13-16 June 2013Therapeutic potential of dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, RP6530, in T-cell Lymphomas |
